supply of coronary drug eluting stentscoronary drug eluting stents,srphc153047-coronary drug eluting stents with (1) cobalt chromium alloy (2) coating of bioabsorbable polymer carrier with abluminal and gradient coating for active drug shown to be effective in preventing neo-intimal hyperplasia) (3) stent diame ter should be from 2.5mm to 4mm . the length of the stent should be from 12mm to 38 m m. (4) the strut thickness should be 91 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compati ble with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) the long term efficacy and safety of the stent the rates of in-stent restenosis (isr) an d in-situ thrombosis (ist) should be documented / published in peer reviewed scientific j ournals. (10) safety of abbreviated (one month) dual antiplatelet therapy for high blee ding risk patients should be documented in peer reviewed journals. (11) the manufacturer/supplier should submit proof of supply of the stent to a major governme nt institute. bis standards for the drug eluting stent are not available. (reference:bis catalogue ). unit:no [ warranty period: 30 months after the date of delivery ] ]